SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 9PM EDT 4 min · 25 Sep 2026 · NPR News Now

HAIR IDEAS THAT ARE SO COOL || Easy Hair Tips And DIY Tricks by 123 GO! 11 min · 25 Sep 2026 · 123 GO!

OTHER PEOPLE VS ME || Funny Relatable Situations and Fails by 123 GO! 11 min · 25 Sep 2026 · 123 GO!

NHL Pacific Division Preview 2026 1h 48m · 25 Sep 2026 · The Steve Dangle Podcast

NPR News: 09-24-2026 8PM EDT 4 min · 25 Sep 2026 · NPR News Now

Fletch, Vaughan & Hayley's Lil Bitta Pod - 25th September 2026 7 min · 25 Sep 2026 · ZM's Fletch, Vaughan & Hayley

Report any issue

Source

Recorded21 Apr 2020

Publisherfeeds.megaphone.fm ↗

Handlerec:11088227

Show notes

Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care. Listen to the episode to hear Dr. Murthy explain: a summary of the study results why this study included people with brain metastases the side effects of tucatinib why she thinks the results are practice changing

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in